COVID-19 vaccine strategies must focus on severe disease and global equity
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
COVID-19 vaccine strategies must focus on severe disease and global equity
Authors
Keywords
-
Journal
LANCET
Volume 399, Issue 10322, Pages 406-410
Publisher
Elsevier BV
Online
2021-12-17
DOI
10.1016/s0140-6736(21)02835-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- COVID-19 serosurveys for public health decision making
- (2021) Manoj V Murhekar et al. Lancet Global Health
- Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies
- (2021) Kayoko Shioda et al. EPIDEMIOLOGY
- Risk of SARS-CoV-2 reinfection after natural infection
- (2021) Rosemary J Boyton et al. LANCET
- Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
- (2021) Joseph E. Ebinger et al. NATURE MEDICINE
- SARS-CoV-2 Antibody Response in Persons with Past Natural Infection
- (2021) Gabriele Anichini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis
- (2021) Alexandra B. Hogan et al. VACCINE
- Evaluation of COVID-19 vaccination strategies with a delayed second dose
- (2021) Seyed M. Moghadas et al. PLOS BIOLOGY
- Individuals cannot rely on COVID-19 herd immunity: Durable immunity to viral disease is limited to viruses with obligate viremic spread
- (2021) Jonathan W. Yewdell PLoS Pathogens
- Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada
- (2021) Sara Carazo et al. CLINICAL INFECTIOUS DISEASES
- Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status
- (2021) David W. Eyre et al. CLINICAL MICROBIOLOGY AND INFECTION
- Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021
- (2021) Sophie Uyoga et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape
- (2021) Fabian Schmidt et al. NATURE
- Has SARS-CoV-2 reached peak fitness?
- (2021) Roberto Burioni et al. NATURE MEDICINE
- Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
- (2021) Dan H. Barouch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis
- (2021) Niklas Bobrovitz et al. PLoS One
- Evolving threat
- (2021) Kai Kupferschmidt SCIENCE
- Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
- (2021) Ahmet Soysal et al. Human Vaccines & Immunotherapeutics
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
- (2021) Shabir A Madhi et al. Lancet HIV
- Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2
- (2021) Sebastian Havervall et al. EBioMedicine
- A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection
- (2021) N. Kojima et al. EVALUATION & THE HEALTH PROFESSIONS
- Immunoglobulin G antibody response to the Sputnik V vaccine: previous SARS-CoV-2 seropositive individuals may need just one vaccine dose
- (2021) Franklin Claro et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
- (2021) Noam Barda et al. LANCET
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
- (2021) Anika Singanayagam et al. LANCET INFECTIOUS DISEASES
- Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination
- (2021) Alice Cho et al. NATURE
- Booster Doses and Prioritizing Lives Saved
- (2021) Minal K. Patel NEW ENGLAND JOURNAL OF MEDICINE
- The Immune Response to SARS-CoV-2 and Variants of Concern
- (2021) Elham Torbati et al. Viruses-Basel
- Effect of a nationwide booster vaccine rollout in Israel on SARS-CoV-2 infection and severe illness in young adults
- (2021) David Bomze et al. Travel Medicine and Infectious Disease
- COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study
- (2021) Utkarsh Agrawal et al. Lancet Respiratory Medicine
- SeroTracker: a global SARS-CoV-2 seroprevalence dashboard
- (2020) Rahul K Arora et al. LANCET INFECTIOUS DISEASES
- Assessing Optimal Target Populations for Influenza Vaccination Programmes: An Evidence Synthesis and Modelling Study
- (2013) Marc Baguelin et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search